EMEA-001050-PIP02-18-M01 - paediatric investigation plan

ixekizumab

Key facts

• Invented name:
  • Taltz
  • Taltz
• Active Substance:
  ixekizumab
• Therapeutic area:
  Immunology-Rheumatology-Transplantation
• Decision number:
  P/0280/2019
• PIP number:
  EMEA-001050-PIP02-18-M01
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Eli Lilly Nederland B.V.

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  16/08/2019

Decision

P/0280/2019: EMA decision of 16 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz), (EMEA-001050-PIP02-18-M01)

AdoptedReference Number: EMA/444267/2019